EZB Stock Overview
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enzo Biochem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.96 |
| 52 Week High | US$2.40 |
| 52 Week Low | US$0.96 |
| Beta | 0.71 |
| 1 Month Change | -16.81% |
| 3 Month Change | -16.09% |
| 1 Year Change | -56.92% |
| 3 Year Change | -61.71% |
| 5 Year Change | -69.72% |
| Change since IPO | -98.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| EZB | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -1.6% | 1.2% |
| 1Y | -56.9% | -3.9% | 2.0% |
Return vs Industry: EZB underperformed the German Healthcare industry which returned -3.9% over the past year.
Return vs Market: EZB underperformed the German Market which returned 2% over the past year.
Price Volatility
| EZB volatility | |
|---|---|
| EZB Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: EZB's share price has been volatile over the past 3 months.
Volatility Over Time: EZB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 185 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.
Enzo Biochem, Inc. Fundamentals Summary
| EZB fundamental statistics | |
|---|---|
| Market cap | €50.17m |
| Earnings (TTM) | -€21.75m |
| Revenue (TTM) | €30.60m |
1.7x
P/S Ratio-2.3x
P/E RatioIs EZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZB income statement (TTM) | |
|---|---|
| Revenue | US$32.80m |
| Cost of Revenue | US$18.97m |
| Gross Profit | US$13.83m |
| Other Expenses | US$37.15m |
| Earnings | -US$23.31m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 42.17% |
| Net Profit Margin | -71.08% |
| Debt/Equity Ratio | 5.0% |
How did EZB perform over the long term?
See historical performance and comparison